Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credit (UAN 0245-0000-17-004-L01-P).

Nursing (ANCC)
This activity is designated for 2.0 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Participants will be provided with instructions for receiving credit through Creative Educational Concepts’ web portal, CE Spectrum, at the live activity.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, and AOCNS® nurses may apply 0.5 points in Scientific Basis/Diagnosis and 1.5 points in Treatment Modalities categories.

ONCC/ILNA Disclaimer
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Needs Statement

The discovery of epidermal growth factor receptor gene (EGFR) mutations in non–small cell lung cancer (NSCLC) and the development of EGFR tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment landscape of EGFR mutation-positive NSCLC. Multiple phase III trials have demonstrated higher response rates and longer durations of progression free survival with first- and second-generation EGFR TKIs when compared to chemotherapy, establishing their place as first-line treatment options for EGFR mutation-positive NSCLC.1-9 However, acquired resistance to first-line EGFR TKIs invariably develops, leading to disease progression in this patient population. The most common mechanism of acquired resistance is the T790M mutation, occurring in 50-60% of patients.10 Third-generation EGFR-TKIs have been developed to specifically target T790M and have demonstrated improved efficacy and durable response in patients who have had disease progression on first-line EGFR-TKI therapy.11,12 However, repeat tissue biopsy to detect acquired T790M resistance is not always possible (often due to lack of an accessible lesion or medical ineligibility due to comorbid conditions). As a result, the use of minimally invasive methods such as plasma-based “liquid” biopsy, are becoming more wide-spread and represent a feasible alternative to tumor biopsy for T790M genotyping.13,14

While delineation of EGFR mutations, the development of targeted therapies, and advances in molecular testing have changed the treatment paradigm of EGFR mutation-positive NSCLC, many questions still remain on how to best move forward in this new era of genomics and precision medicine in patients with NSCLC.

This interactive symposium will use a debate-style format to examine evolv-ing clinical data and emerging treatment strategies for the management of advanced EGFR mutation-positive NSCLC. Faculty will provide expert perspec-tives regarding clinical questions related to the role of specific EGFR mutation type (exon 19 vs. 21) in TKI selection, the utility of ctDNA testing to detect EGFR mutations, optimal strategies for treating T790M acquired resistance, and emerging treatment strategies for EGFR mutation-positive NSCLC with brain or leptomeningeal metastases.

1Mok TS, et al. N Engl J Med. 2009; 2Maemondo M, et al. N Engl J Med. 2010; 3Mitsudomi T, et al. Lancet Oncol. 2010; 4Han JY, et al. J Clin Oncol. 2012; 5Zhou C, et al. Lancet Oncol. 2011; 6Rosell R, et al. Lancet Oncol. 2012; 7Sequist LV, et al. J Clin Oncol. 2013; 8Yang JC, et al. Lancet Oncol. 2015; 9Masters GA, et al. J Clin Oncol. 2015; 10Tan CS, et al. Lancet Oncol. 2015; 11Jänne PA, et al. N Engl J Med. 2015; 12Mok TS, et al. N Engl J Med. 2017; 13Mok TS, et al. Clin Cancer Res. 2015. 14Oxnard GR, et al. J Clin Oncol. 2016.


At the conclusion of this knowledge-based activity, participants will be able to:

1. Explore emerging issues in optimal management of advanced EGFR mutation-positive NSCLC.

2. Evaluate evolving treatment approaches used to overcome EGFR resistance in advanced NSCLC using EGFR TKIs.

3. Appraise the current status of clinical development of EGFR TKIs as part of combination therapies.

4. Assess treatment approaches used to treat patients with EGFR mutation-positive NSCLC and brain or leptomeningeal metastases.

5. Differentiate recommended molecular testing and role for ctDNA in detecting EGFR mutations, including T790M.

Target Audience

This activity is targeted towards clinical oncologists and oncology specialty pharmacists and nurses attending the 2017 ASCO Annual Meeting who are involved in selecting therapeutic regimens for patients with NSCLC.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in educational presentations. Relevant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.

Adrienne Matson, PharmD, BCPS - has no relevant financial relationships to disclose in relation to the content of this activity.

Pasi A. Jänne, MD, PhD - has disclosed that he is a consultant for ARIAD, AstraZeneca, Boehringer Ingelheim, Chugai, Merrimack, Pfizer, and Roche; receives grant/research support from Astellas and AstraZeneca; and receives other financial or material support from Gatekeeper Pharmaceuticals and LabCorp.

Mark G. Kris, MD, FACP, FACCP – has disclosed that he is a consultant for AstraZeneca. 

Tony S.K. Mok, BMSc, MD, FRCPC - has disclosed that he is a consultant for  AstraZeneca, Boehringer Ingelheim, Lilly, Merck, and Pfizer; receives grant/research support from AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Roche, MSD, and SFJ Pharmaceuticals Group; is a major stock shareholder in Sanomics Ltd.

Suresh S. Ramalingam, MD – is a consultant for Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Celgene, Genentech, Lilly, Merck, and Novartis.

Lecia V. Sequist, MD, MPH - has disclosed that she is a consultant for ARIAD, AstraZeneca, Bristol-Myers Squibb, and Genentech. 

Peer Reveiwers:

Josiah D. Land, PharmD, BCOP (Memorial Sloan Kettering, New York, NY) – has no relevant financial relationships to disclose in relation to the content of this activity.

Gregory J. Riely, MD, PhD (Memorial Sloan Kettering, New York, NY) – has disclosed that he receives grant/research support from Ariad, Novartis, Pfizer, and Roche/Genentech.

Vicki Sherry, DNP, CRNP, ANP-BC, AOCNP (University of Pennsylvania, Philadelphia, PA) - has no relevant financial relationships to disclose in relation to the content of this activity.